Title: Fiona Farr BSc
1Lowering a vital drawbridge
- Fiona Farr BSc Nigel Griffiths BSc PhD
MEDICAL MARKETING RESEARCH International
MEDICAL MARKETING STUDIES, US Inc. THE KOL
EXPERTS Working with KOLs for gt15yrs
2The objective...
- What do the worlds top OPINION LEADERS in 5
markets of critical interest to the Industry have
to say about a Pharmaceutical Industry Under
Siege?
3Agenda
- Methodology Guaranteeing objectivity and a true
measure of influence - OPEXTM
- Opinion Leader Insight Study
- Case Study The pharmaceutical industry under
siege - What do the KOLs want from industry?
- What can the industry get from partnering with
KOLs? - How good are pharmaceutical companies at
communicating commitment to advancement of
healthcare? - Who are the peacemakers? Who pours boiling oil?
- How can agencies optimize the way they work with
Opinion Leaders? - Lowering some drawbridges
4How are Opinion Leaders traditionally identified?
5Ask the Marketplace...
We have developed our own methodology (over the
last 15 years) to identify Opinion Leaders based
on peer nomination OPEXTM
We approach these objectively identified KOLs in
our KOL market research studies
6Who did we speak to in this research?
- Professors at the top universities
- Speakers at international congresses
- Government advisors
- Consultants on pharmacos scientific advisory
boards
Boehringer Ingelheim
Novartis
AstraZeneca
Pfizer
JJ
Merck
Lilly
BMS
GSK
these are the KOLs you are working closely
with and are the individuals who INFLUENCE
OPINIONS OF YOU AND YOUR PRODUCTS
7The KOL tightrope
8What does a KOL seek from the pharmaceutical
industry?
A place at the cutting edge
Research
Platform/ Prestige
Foreknowledge
Advancement of their thinking
Personal
9What do KOLs have to offer the pharmaceutical
industry?
RD Advice
Objective synthesis
Global overview
Education (medics)
Strategic input
Marketing Guidance
Product Advocacy
10How good are pharmaceutical companies at
communicating commitment to advancement of
healthcare?
THE MOST CONCERNING FINDING
- and were not aware of anything being done to
address this negative image.
11Who does it well? Who does it badly?
- The Researchers, The Scientists, The Educators
- Poor communicators e.g. of the rationale for
costing
- Team up with non profit-
- making organizations
- Complacency e.g. re off-label indications
- Research grants to look at more than their own
drug
- The me-too approach to development
commercially, not scientifically driven
- The groundbreakers who answer scientifically
meaningful Qs
- Those who pursue surrogate markers and not QoL
12What do KOLs want to give the industry?
13The dos and don'ts of relationship building
DONT
- Try to control them telling them exactly how,
what and when to present - Slip into the hired gun trap
- Overtly sell
- Slam your competitors
- Discourage frankness
- Rely on CROs to be your ambassador
14The dos and don'ts of relationship building
DO
- Identify with their mission for the betterment of
pts - Give feedback on their contribution
- Provide a stimulating and unbiased (or less
biased) forum for discussion - Support investigator-initiated research which
explores the wider scientific questions - Communicate the basis of their selection
- Involve them in education
- Have Specialist KOL liaison (with continuity of
contact) - Pay them well!
15Recent tightening of conflict of interest
regulations
- NEGATIVE
- Too stringent
- A licence for censorship by pharmacos?
- POSITIVE
- Transparency expected and needed in this sector
16How can agencies improve the way they work with
KOLs?
THE MOST WELCOME FINDING!
OVERALL, VERY POSITIVE FEEDBACK
Areas to improve on
- Knowledge of interviewer
- Remembering the true meaning of in-depth
- Not asking about drug costs or demographics
- Considered use of on-line discussions with
multiple feedback sessions
Key recommendation
Use us post-launch as well
17Concluding thoughts.
18Lowering the drawbridge to CONSUMERS...
19Lowering the drawbridge to OPINION LEADERS...
Get the balance right!
20and finally your homework in Naples
I hear and I forget... I see and I
remember... I do and I understand. Confuciu
s
- Thanks for your attention!